Cancer incidence and mortality are higher in African-Americans for almost every kind of cancer. The Virginia Commonwealth University (VCU) Minority-Based Community Clinical Oncology Program (MBCCOP) is designed to increase the availability of state-of-the-art cancer treatment and cancer prevention and control research trials to the urban and rural minorities of Richmond and Southside Virginia. Over forty percent of new cancer cases seen in the VCU MBCCOP are minority, nearly all African-Americans. Organizational and operational plans, which will provide the structure for the effective implementation of multidisciplinary research, are presented. This application emphasizes the unique urban and rural population available to the VCU MBCCOP, the history of extensive participation by primary health care providers and specialists, in particular, surgeons and pediatric oncologists, in clinical research at VCU, and VCU initiatives in cancer outreach conducted at rural MBCCOP sites. Currently, the VCU MBCCOP has affiliations with three research bases: NSABP, CALGB, and COG. It is seeking CCOP affiliation with GOG. It also participates in trials available through the Cancer Trials Support Unit (CTSU). The application describes the working relationships with the research bases and the methods used to enable the VCU MBCCOP to accrue significant numbers of minority participants to both treatment and cancer prevention and control clinical trials. Working relationships of the VCU MBCCOP investigators and the clinical research teams aredescribed. The role of the MBCCOP in bringing state-of-the-art treatment and cancer prevention and control studies to traditionally underserved segments of the population, urban and rural minorities, is discussed, and successes to date by the VCU MBCCOP are described.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRRB-D (J1))
Program Officer
Mccaskill-Stevens, Worta J
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Virginia Commonwealth University
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Himelstein, Andrew L; Foster, Jared C; Khatcheressian, James L et al. (2017) Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. JAMA 317:48-58
Uy, Geoffrey L; Mandrekar, Sumithra J; Laumann, Kristina et al. (2017) A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. Blood Adv 1:331-340
Ports, Katie A; Ayers, Antoinette; Crocker, Wayne et al. (2015) Community perceptions and utilization of a consumer health center. J Med Libr Assoc 103:35-9
Rafie, Carlin; Ayers, Antoinette; Cadet, Debbie et al. (2015) Reaching Hard to Reach Populations with Hard to Communicate Messages: Efficacy of a Breast Health Research Champion Training Program. J Cancer Educ 30:599-606
Mosavel, Maghboeba; Rafie, Carlin; Cadet, Debbie L et al. (2012) Opportunities to reduce cancer barriers: community town halls and provider focus groups. J Cancer Educ 27:641-8
Bertagnolli, Monica M; Redston, Mark; Compton, Carolyn C et al. (2011) Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer--a study of CALGB 9581 and 89803. J Clin Oncol 29:3153-62
Paschka, Peter; Marcucci, Guido; Ruppert, Amy S et al. (2008) Wilms'tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol 26:4595-602
Silverman, Lewis R; McKenzie, David R; Peterson, Bercedis L et al. (2006) Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 24:3895-903
Lamont, Elizabeth B; Herndon 2nd, James E; Weeks, Jane C et al. (2006) Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344). J Natl Cancer Inst 98:1335-8
Halabi, Susan; Vogelzang, Nicholas J; Ou, San-San et al. (2006) Clinical outcomes by age in men with hormone refractory prostate cancer: a pooled analysis of 8 Cancer and Leukemia Group B (CALGB) studies. J Urol 176:81-6

Showing the most recent 10 out of 22 publications